Stoke Therapeutics (STOK) Competitors $9.48 -0.57 (-5.67%) Closing price 04:00 PM EasternExtended Trading$9.48 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. VCEL, NAMS, GMTX, AAPG, BLTE, HRMY, DNLI, KYMR, KNSA, and CGONShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Vericel (VCEL), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), Harmony Biosciences (HRMY), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Kiniksa Pharmaceuticals (KNSA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Vericel NewAmsterdam Pharma Gemini Therapeutics Ascentage Pharma Group International Belite Bio Harmony Biosciences Denali Therapeutics Kymera Therapeutics Kiniksa Pharmaceuticals CG Oncology Stoke Therapeutics (NASDAQ:STOK) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Do analysts rate STOK or VCEL? Stoke Therapeutics presently has a consensus target price of $23.20, suggesting a potential upside of 142.17%. Vericel has a consensus target price of $60.86, suggesting a potential upside of 46.12%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is STOK or VCEL more profitable? Vericel has a net margin of 1.56% compared to Stoke Therapeutics' net margin of -629.90%. Vericel's return on equity of 1.48% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Vericel 1.56%1.48%0.96% Does the media favor STOK or VCEL? In the previous week, Stoke Therapeutics had 30 more articles in the media than Vericel. MarketBeat recorded 36 mentions for Stoke Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.42 beat Stoke Therapeutics' score of 0.76 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer STOK or VCEL? Vericel received 234 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 76.58% of users gave Stoke Therapeutics an outperform vote while only 61.74% of users gave Vericel an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes12176.58% Underperform Votes3723.42% VericelOutperform Votes35561.74% Underperform Votes22038.26% Which has higher earnings and valuation, STOK or VCEL? Vericel has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$190.91M2.74-$104.70M$0.7912.13Vericel$238.54M8.79-$3.18M$0.031,388.33 Which has more risk and volatility, STOK or VCEL? Stoke Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. SummaryVericel beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$522.49M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-4.568.9726.6219.77Price / Sales2.74253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book2.686.486.814.53Net Income-$104.70M$143.98M$3.23B$248.18M7 Day Performance6.56%3.37%4.05%1.06%1 Month Performance11.27%7.83%11.64%14.68%1 Year Performance-37.59%-2.24%17.11%6.87% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.6463 of 5 stars$9.48-5.7%$23.20+144.7%-37.6%$517.58M$190.91M-4.51100Analyst RevisionGap DownVCELVericel2.5802 of 5 stars$42.54+0.1%$60.86+43.1%-14.9%$2.14B$238.54M709.12300Positive NewsNAMSNewAmsterdam Pharma2.5235 of 5 stars$19.03+0.8%$43.00+126.0%-2.5%$2.09B$47.14M-10.124Positive NewsGMTXGemini TherapeuticsN/A$48.09+2.1%N/A+54.4%$2.08BN/A-48.0930High Trading VolumeAAPGAscentage Pharma Group InternationalN/A$23.78+5.0%N/AN/A$2.07B$980.65M0.00600Gap UpBLTEBelite Bio2.0704 of 5 stars$65.00+0.9%$96.67+48.7%+43.5%$2.07BN/A-58.5610News CoverageAnalyst RevisionGap UpHRMYHarmony Biosciences4.8079 of 5 stars$35.91+2.4%$52.78+47.0%+19.9%$2.06B$744.85M17.02200Positive NewsDNLIDenali Therapeutics4.4338 of 5 stars$13.91+0.9%$33.71+142.4%-29.0%$2.02B$330.53M-5.04430Analyst ForecastKYMRKymera Therapeutics2.5499 of 5 stars$30.20-0.2%$55.27+83.0%-12.7%$1.97B$58.89M-12.91170Analyst ForecastGap DownKNSAKiniksa Pharmaceuticals2.9674 of 5 stars$26.74+1.9%$38.80+45.1%+35.7%$1.95B$481.17M-190.99220Positive NewsCGONCG Oncology2.2351 of 5 stars$24.86-2.2%$58.22+134.2%-10.7%$1.89B$662,000.00-16.4661Analyst Forecast Related Companies and Tools Related Companies VCEL Alternatives NAMS Alternatives GMTX Alternatives AAPG Alternatives BLTE Alternatives HRMY Alternatives DNLI Alternatives KYMR Alternatives KNSA Alternatives CGON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STOK Stock Free STOK Stock Alerts